Global investment firm KKR� (NYSE: KKR ) is acquiring global contract research organization PRA International from San Francisco-based private equity firm�Genstar Capital for an undisclosed sum, PRA announced today. The New York Times reports that a "person briefed on the matter" said the price was about $1.3 billion.
PRA is one of the world's biggest CROs with�more than 5,300 employees located in more than 50 offices worldwide, performing approximately 2,000 clinical trials in more than 80 countries for more than 300 clients since 2000.
That was underlined by KKR Health Care investing team member�Jim Momtazee, who was quoted as saying, "As one of the fastest growing companies in the CRO sector, PRA is known for its strong client relationships and differentiated therapeutic expertise."
The services PRA provides on a contract basis to the pharmaceutical and biotechnology industries include filing Investigational New Drug and similar regulatory applications, management and implementation of phase I through IV clinical trials, preparation and submission of New Drug Applications, and post-marketing surveillance.
5 Best Communications Equipment Stocks To Buy Right Now: TriMas Corporation(TRS)
TriMas Corporation designs, manufactures, and distributes various products for commercial, industrial, and consumer markets worldwide. Its Packaging segment offers steel and plastic closure caps, drum enclosures, rings and levers, and specialty plastic closures, as well as dispensing systems, such as pumps and specialty sprayers to store, transport, process, and dispense various products for industrial, agricultural, food, beverage, personal care, pharmaceutical, nutraceutical, and medical markets. The company?s Energy segment provides metallic and non metallic gaskets; and various types of stud bolts, industrial fasteners, and specialty products for petroleum refining, petrochemical, oil field, and industrial markets. Its Aerospace and Defense segment offers aerospace fasteners and military munitions components to serve aircraft and weapons platforms in the aerospace and defense industries. The company?s Engineered Components segment provides natural gas engines and par ts, compressors, gas production equipment, and chemical pumps engineered for well sites for the oil and gas industry; and high-pressure and low-pressure cylinders for the transportation, storage, and dispensing of compressed gases. Its Cequent Asia Pacific and Cequent North America segments offer custom-engineered towing, trailering, and electrical products, including trailer couplers, winches, jacks, trailer brakes and brake control solutions, lighting accessories, and roof racks for recreational vehicle, agricultural/utility, marine, automotive, and commercial trailer markets; and functional vehicle accessories and cargo management solutions comprising vehicle hitches and receivers, sway controls, weight distribution and fifth-wheel hitches, hitch-mounted accessories, and other accessory components. The company sells its products through direct sales force, third‑party agents, distributors, licensees, and independent sales representatives. TriMas Corporation is based in Bloomfield Hills, Michigan.
Advisors' Opinion:- [By cody56]
During the third quarters these holdering were the worse performers for Diamond Hill Small Cap Fund. Rosseta Resources Inc. (ROSE) , TriMas Corp. (TRS) , Tenneco Inc. (TEN) , Popular Inc. (BPOP) and Hub Group (HUBG).
- [By Luke Jacobi]
Shares of TriMas (NASDAQ: TRS) were down 10 percent to $26.59 after the company cut its full-year profit outlook. The company also announced its plans to buy Allfast Fastening Systems for around $360 million.
- [By Garrett Cook]
Basic materials sector was the top decliner on Monday. Top losers in the sector included TriMas (NASDAQ: TRS), down 9.9 percent, and Cliffs Natural Resources (NYSE: CLF), off 8.5 percent.
Hot International Companies To Watch In Right Now: Flushing Financial Corporation (FFIC)
Flushing Financial Corporation operates as the holding company of Flushing Savings Bank, FSB that provides banking products and services primarily to consumers and businesses. The company?s deposit products include savings accounts, money market accounts, demand accounts, negotiable order of withdrawal accounts, and certificates of deposit. Its loan products portfolio comprises one-to-four family, multi-family residential, and commercial real estate mortgage loans; construction loans, primarily for residential properties; small business administration loans and other small business loans; mortgage loan surrogates, such as mortgage-backed securities; U.S. government securities, corporate fixed-income securities, and other marketable securities; and consumer loans, including overdraft lines of credit. The company also offers Internet banking services through iGObanking.com. As of December 31, 2010, it conducted its business through 16 full-service offices located in the New York City Boroughs of Queens, Brooklyn, and Manhattan, as well as in Nassau County, New York. The company was founded in 1929 and is based in Lake Success, New York.
Advisors' Opinion:- [By Marc Bastow]
Savings and loan holding company Flushing Financial (FFIC) raised its quarterly dividend 15% to 15 cents per share, payable March 28 to shareholders of record as of March 7.
FFIC Dividend Yield: 2.86% - [By Tim Melvin]
I always find it very interesting to see what long-term investors are selling in a given quarter. Kahn Brothers lightened up on many financials that have shot up and now trade above book value. The firm sold out of Flushing Financial (FFIC), TCF Financial (TCB) and Dime Community Bank (DCOM). Khan apparently shares my views on the large-cap drug stocks, easing up on both Pfizer (PFE) and Bristol Meyers (BMY) over the summer. Khan Brothers also sold the last of the Travelers shares (TRV) it has owned since 2008 at more than twice the purchase price.
Hot International Companies To Watch In Right Now: Therapeutic Solutions International Inc (TSOI)
Therapeutic Solutions International, Inc., formerly Friendly Auto Dealers, Inc., incorporated on August 6, 2007, is a development-stage company. The Company is focused in establishing itself as a specialized brand promotional merchandising company. It would identify a range of casual apparel and consumer products that can be manufactured and resold with the product endorsement of corporate logos. In April 2011, the Company acquired Splint Decisions Inc.
The Company concentrates its efforts in the People�� Republic of China and its retail automotive industry. As of December 31, 2009, the Company had no operations and had not generated any revenues.
Advisors' Opinion:- [By Peter Graham]
Small cap medical device or biotech related stocks Therapeutic Solutions International Inc (OTCMKTS: TSOI), diaDexus, Inc (OTCMKTS: DDXS) and Spherix Inc (NASDAQ: SPEX) have been getting some attention lately in various investment newsletters with the good news being that it appears none are the subject of paid promotions from stock promoters. So why are these three stocks all of a sudden getting some attention and what else do you need to know about them before you make a short or a long term bet on one? Here is a closer look at the whole picture and what you might be missing:
Hot International Companies To Watch In Right Now: Allscripts Healthcare Solutions Inc.(MDRX)
Allscripts Healthcare Solutions, Inc. provides clinical, financial, connectivity, and information solutions and related professional services to hospitals, physicians, and post-acute organizations primarily in the United States and Canada. The company?s integrated clinical software applications include acute care electronic health records, clinical and practice management solutions, revenue cycle management software, clearinghouse services, stand-alone electronic prescribing, and document imaging solutions, as well as various solutions for home care, hospice, skilled nursing, and other post-acute organizations. It also provides electronic medical records software; practice management software; electronic claims administration services; related installation and training services; hosting services for its software and outsourced solutions; and information technology outsourcing services. In addition, the company also resells related hardware products. Allscripts Healthcare Solutions, Inc. is headquartered in Chicago, Illinois.
Advisors' Opinion:- [By Dan Caplinger]
One big opportunity that Quality Systems will try to cash in on this year is the trend toward medical professionals switching their electronic-health-records vendors. With one survey showing that as many as 1-in-6 of every users wanting to make a change, the industry could go through a big upheaval. Unfortunately for Quality Systems, its customer rankings are relatively low, and it appears that rival athenahealth (NASDAQ: ATHN ) could end up drawing business away from Quality Systems and peer Allscripts (NASDAQ: MDRX ) based on their respective perceptions by customers.
- [By Keith Speights]
As you might expect, large EHR systems vendors enthusiastically welcomed passage of HITECH. What company wouldn't enjoy having the government pay customers to buy its products and fine them if they didn't? Allscripts (NASDAQ: MDRX ) reported total revenue of $548 million in the fiscal year ending in May 2009. At the end of 2012, the company's annual revenue topped $1.4 billion -- thanks in no small part to Uncle Sam.
Hot International Companies To Watch In Right Now: Neurocrine Biosciences Inc.(NBIX)
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; GnRH Antagonists for men?s and women?s health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott International Luxembourg S.�r.l. to develop and commercialize elagolix and GnRH antagonists for women?s and men?s health indications; and Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Ben Levisohn]
Yes, say the folks at Nomura, who recommend buying�Celgene (CELG), Receptos
(RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why: - [By Jake L'Ecuyer]
Equities Trading UP
Shares of Neurocrine Biosciences (NASDAQ: NBIX) got a boost, shooting up 57.43 percent to $15.37 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study. - [By Roberto Pedone]
Another stock that's starting to trend within range of triggering a major breakout trade is Neurocrine Biosciences (NBIX), which discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. This stock has been a hot name with bulls so far in 2013, with shares up 57%.
If you look at the chart for Neurocrine Biosciences, you'll notice that this stock recently gapped down sharply from $16.74 to below $11.50 a share with heavy downside volume flows. Following that gap down, shares of NBIX went on to continue its trend lower and the stock hit a new low of $10.42 a share. Shares of NBIX have started to rebound off that $10.42 low and it's now moving within range of triggering a major breakout trade.
Traders should now look for long-biased trades in NBIX if it manages to break out above some near-term overhead resistance levels at its 200-day moving average of $11.92 a share and above its gap down day high of $12.17 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 894,145 shares. If that breakout triggers soon, then NBIX will set up to re-fill some of its previous gap down zone from September that started at $16.74 a share. Some possible upside targets for NBIX if it gets into that gap with volume are $14 to $15 a share.
Traders can look to buy NBIX off any weakness to anticipate that breakout and simply use a stop that sits right below support at $11 a share, or below that recent low of $10.42 a share. One can also buy NBIX off strength once it takes out that breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment